THIS IS AN ONLINE E LOG BOOK TO DISCUSS OUR PATIENT'S DE-IDENTIFIED HEALTH DATA SHARED AFTER TAKING HER SIGNED INFORMED CONSENT. HERE WE DISCUSS OUR PATIENT'S PROBLEMS THROUGH SERIES OF INPUTS FROM AVAILABLE GLOBAL ONLINE COMMUNITY EXPERTS WITH AN AIM TO SOLVE THOSE PATIENT'S CLINICAL PROBLEMS WITH COLLECTIVE CURRENT BEST EVIDENCE BASED INPUTS.
[4.46 pm, 21/02/2026] PPM 1: 56F with chronic dry cough, fever, night sweats and weight loss since mid 2024.
No documented treatment with Antitubercular therapy in spite of suspicious shadows since mid 2024 as attached here.
PPM3 do share her chest X-ray pa view done today if possible.
[1:08 pm, 23/02/2026] PPM 1: @PPM4 can you ask @PPM3 to add the ward brother who's one of her distant patient advocates here so that we can get to know from him if her sputum AFB was tested from our local rntep here
This is the recent chest X-ray attached
[1:14 pm, 23/02/2026] PPM 4: Ok sir
[4:10 pm, 25/02/2026] PPM 1: Kochs postulates still not satisfied. Next we'll need to go ahead with HRCT chest and Fibre optic bronchoscopy before we give up and start empirical antitubercular therapy
[4:11 pm, 25/02/2026] PPM 1: @PPM5 shift her out of isolation.
[4.12 pm, 25/02/2026] PPM 1: If they are unable to afford CT and or bronchoscopy then we can start her on empirical antitubercular therapy ASAP.
Please share the note by chest and TB department @PPM3
[4:13 pm, 25/02/2026] PPM 5: ok sir
[4:14 pm, 25/02/2026] PPM 3: Ok sir
[4:52 pm, 25/02/2026] PPM 2: That's TB
[5:03 pm, 25/02/2026] PPM 1: Yes since 2024 without any antitubercular therapy and currently sputum negative
[5:04 pm, 25/02/2026] PPM 2: But with chronic symptoms?
[5:06 pm, 25/02/2026] PPM 1: Yes since 2024
[5:09 pm, 25/02/2026] PPM 2: How much of that sputum was actually sputum? CBNAAT 95+% sensitive and specific. Because pre test probability is very high, I would send a sample again with nebuliser help and make sure it is actual sputum.
[5:12 pm, 25/02/2026] PPM 1: This sample had to be given two towns away as currently it's not being done here and the report took two days to arrive
[5:16 pm, 25/02/2026] PPM 2: Hmmm. Do you want to empirically treat it then?
[6:58 pm, 25/02/2026] PPM 1: Will take a shot at further imaging and bronchoscopy BAL and if negative will start ATT empirically or @PPM5 we can even start tomorrow even as get those tests done
[7:00 pm, 25/02/2026] PPM 3: Attenders said they will arrange money by tommorrow, will plan hrct tommorrow, followed by bal day after tomorrow sir
[7:08 pm, 25/02/2026] PPM 1: And either way we can begin her ATT tomorrow.
Please share the deidentified chest and TB notes
[7:10 pm, 25/02/2026] PPM 3: It's in the casesheet sir, I don't have a photo of it, will share it Tommorrow sir
[11:15 am, 27/02/2026] PPM 3: Brochoscopy was done yesterday sir
[11:34 am, 27/02/2026] PPM 3:
[11:40 am, 27/02/2026] PPM 1: Thanks for sharing.
So while the macroscopic bronchoscopy findings are unimpressive , we may now have to wait for the organism to call the shots @PPM6 or more likely we shall simply go ahead with antitubercular therapy even if we don't find the organism and we can't satisfy all of Kochs postulates. @PPM4 what about her Hrct images? Can we share those here?
[12:08 pm, 27/02/2026] PPM 1: 👆@CR @PPM2 @PaJR Health patient identifiers are visible and will need to be removed manually whenever feasible.
[12:09 pm, 27/02/2026] PPM 1: Who has reported this?
This section attached shows what looks like a peripheral parenchymal cavity rather than a disproportionately dilated bronchiectasis? @PPM7 @PaJR Health @PPM8
[1237 pm, 27/02/2026] PPM 7: It’s clear you’ve been looking closely at these scans, and distinguishing between those two findings is a common challenge even for experienced clinicians.
[1237 pm, 27/02/2026] PPM 7: It’s clear you’ve been looking closely at these scans, and distinguishing between those two findings is a common challenge even for experienced clinicians.
Regarding the Report
I cannot tell who reported this scan. The identifying information (such as the radiologist's name, the hospital, or the patient's details) has been redacted or is not visible in the photos provided. To find the official interpretation, you would need the physical paper report or access to the electronic medical record where the scan was performed.
Cavity vs. Cystic Bronchiectasis
You’ve raised a very technical point. In imaging, the distinction often comes down to the wall thickness and the "neighborhood" the lesion is in.
* Peripheral Parenchymal Cavity: This is a gas-filled space within a region of lung consolidation, a mass, or a nodule. It typically has thicker, more irregular walls and occurs where lung tissue has been destroyed (necrosis).
* Cystic Bronchiectasis: This is the extreme dilation of the bronchi. They often look like a "string of pearls" or a "bunch of grapes." The walls are usually thinner than a typical cavity, and you can often trace them back to the central airway system.
Observations on the Images
Looking at the zoomed-in section and the reconstructions:
* The Appearance: You are correct that there are several lucent (dark, air-filled) areas with relatively defined walls. Some of these, particularly the ones surrounded by denser white areas (consolidation), do have the classic appearance of cavities.
* The Difficulty: Without being able to "scroll" through the digital slices (the original DICOM files), it’s hard to see if these spaces connect directly to the bronchial tree. If they connect, they lean toward bronchiectasis; if they are isolated "holes" in a solid area, they are likely cavities.
* Context Matters: The overall pattern—showing multiple areas of involvement across both lungs—often suggests an underlying process like a chronic infection (like TB or fungal infections) or an inflammatory condition.
Important Next Step
Interpreting lung CTs requires correlating these images with your clinical symptoms (like cough, fever, or weight loss) and previous health history.
Have you already received the written report from the radiologist, or are you waiting for a follow-up appointment with a pulmonologist? If you have the report text, I can help you break down the terminology used there.
Based on the images provided and the clinical context from the *Daily Log, here is a synthesis of the current findings for the **56F* patient presenting with chronic cough, fever, and weight loss.
*CLINICAL INTERPRETATION OF IMAGING*
The images shared appear to be coronal reconstructions of a CT chest. There are several key patterns visible that align with the patient's long-standing symptoms:
🔹 *CAVITARY LESIONS:* There are distinct air-filled spaces with relatively thick walls, particularly in the upper zones. In a patient with a two-year history of constitutional symptoms (fever, weight loss), these are highly suggestive of chronic granulomatous disease, most commonly *Pulmonary Tuberculosis (PTB)*.
🔹 *RETICULONODULAR OPACITIES:* Surrounding the lucent areas, there is evidence of increased density (white areas) which likely represent a mix of consolidation and chronic fibrotic changes.
🔹 *DIFFERENTIAL CONSIDERATIONS:* While TB is the primary suspect given the "sputum negative" but "chronic symptom" profile, other possibilities include:
* *Chronic Pulmonary Aspergillosis:* Often complicates pre-existing cavities.
* *Nontuberculous Mycobacteria (NTM):* Can present identically to TB in chronic cases.
* *Cystic Bronchiectasis:* As previously noted in the log, if these lucencies connect to the airways, they may represent severe bronchial dilation.
*CORRELATION WITH RECENT PROCEDURES*
📋 *56F chronic cough, fever, night sweats, weight loss 2024 WB PaJR*
💡 *CLINICAL NOTE*
The log indicates that *Bronchoscopy (BAL)* was performed yesterday. While macroscopic findings were "unimpressive," the definitive answer lies in the *BAL fluid analysis* (GeneXpert/CBNAAT, AFB culture, and Cytology).
Given the high pre-test probability and the clear cavitary disease on the CT, the decision discussed in the records to begin *Empirical Antitubercular Therapy (ATT)* is a standard clinical path when diagnostic yield is hampered by logistical delays or "sputum negative" status in a symptomatic patient.
*NEXT STEPS*
1. Monitor for clinical response (improvement in fever/appetite) once ATT is initiated.
2. Await the BAL culture results, as these will confirm the organism and its drug sensitivity profile.
3. Ensure the patient is moved out of isolation only if the clinical team is satisfied with the infection control protocols for "sputum negative" cavitary cases.
This clinical context from the PaJR log adds a massive piece to the puzzle. We are looking at a 56-year-old female with classic "B symptoms" (weight loss, night sweats, fever) and a chronic cough lasting nearly two years.
Who reported this?
The log doesn't name the radiologist. It shows a discussion between a medical team (PPM 1 through 5). Based on the conversation, the formal radiologist’s report might not even be written yet, as PPM 3 mentioned they were only planning to arrange the HRCT on February 26th.
The clinicians in the chat (specifically PPM 1 and PPM 2) are the ones currently "reporting" or interpreting it in real-time to decide on Empirical Antitubercular Therapy (ATT).
Cavity vs. Cystic Bronchiectasis
You are leaning toward a peripheral parenchymal cavity, and given this clinical history, your intuition is likely more accurate than a diagnosis of simple bronchiectasis. Here is why:
* Wall Characteristics: In the zoomed-in image (1000312478.jpg), the air-filled space has a thick, irregular wall and is surrounded by "fluffy" white areas (consolidation). This is classic for a cavity formed by tissue necrosis (death of lung tissue).
* The "Tree-in-Bud" Sign: If you look at the peripheral areas of the CT, there are small branching dots. This often indicates endobronchial spread of an infection—very common in active Tuberculosis.
* Clinical Correlation: Cystic bronchiectasis is a structural "tubing" problem. While it can cause a chronic cough, it doesn't typically cause progressive weight loss and night sweats unless there is a secondary massive infection. A cavitary lesion, however, is the "smoking gun" for active, infectious TB (hence PPM 2's comment: "That's TB").
> The Verdict: You are likely correct. While TB can cause "traction bronchiectasis" (pulling the airways open due to scarring), the large, dark, thick-walled circles seen here in the upper lobes are much more consistent with cavitary lung disease.
>
The "Sputum Negative" Dilemma
The log mentions the sputum was negative, but PPM 2 makes a vital point: if the pre-test probability is high (which it is here), a negative result should be questioned. This is exactly why they are moving to Bronchoalveolar Lavage (BAL)—to get a sample directly from the source of those cavities.
Would you like me to help you understand the difference between the "Empirical ATT" they are discussing and the standard treatment protocol?
The last AI response was from Gemini btw @PPM1 Sir @PPM8
This clinical context from the PaJR log adds a massive piece to the puzzle. We are looking at a 56-year-old female with classic "B symptoms" (weight loss, night sweats, fever) and a chronic cough lasting nearly two years.
Who reported this?
The log doesn't name the radiologist. It shows a discussion between a medical team (PPM 1 through 5). Based on the conversation, the formal radiologist’s report might not even be written yet, as PPM 3 mentioned they were only planning to arrange the HRCT on February 26th.
The clinicians in the chat (specifically PPM 1 and PPM 2) are the ones currently "reporting" or interpreting it in real-time to decide on Empirical Antitubercular Therapy (ATT).
Cavity vs. Cystic Bronchiectasis
You are leaning toward a peripheral parench
👆@PPM7 this was from Gemini?
This is a well-documented case discussion from the PaJR platform. Based on the chronology and the expert inputs, here is a structured analysis and a proposed plan of action that synthesizes the collective intelligence of the team.
### Analysis of the Case So Far
*Patient:* 56-year-old Female
*Presentation:* Classic B-symptoms (fever, night sweats, weight loss) with a chronic dry cough since mid-2024.
*Key Timeline:*
- *Mid-2024:* Suspicious shadows on chest imaging. No treatment initiated.
- *21 Feb 2026:* Presents with persistent symptoms. New CXR done.
- *23 Feb 2026:* Recent CXR shows abnormalities.
- *25 Feb 2026:* Sputum CBNAAT (GeneXpert) is negative. The team discusses the next steps: HRCT, Bronchoscopy with BAL, vs. empirical Antitubercular Therapy (ATT).
### Key Clinical Questions and Considerations
1. *High Pre-Test Probability:* This patient has a high likelihood of tuberculosis (TB). The chronic history of B-symptoms combined with radiological shadows is highly suggestive, especially in a TB-endemic setting like India.
2. *The Negative CBNAAT:* As Dr. PPM2 pointed out, while CBNAAT is highly sensitive, it is not 100%. A negative result on a sputum sample that might not have been optimal (induced or deep cough) does not rule out TB, particularly if the disease is pauci-bacillary or if the radiological shadow is not communicating with the airway (e.g., a tuberculoma or fibrotic lesion).
3. *Resource Limitations:* The family has financial constraints, which is a critical factor in the decision-making process. The goal is to balance the need for a definitive diagnosis with the risk of disease progression and the cost of investigations.
4. *Infection Control:* The patient was initially in isolation. Given the negative sputum CBNAAT and the absence of a confirmed airborne disease, shifting her out of isolation (as per Dr. PPM1's instruction) is a reasonable step to free up resources, provided she is not coughing profusely.
### A Proposed Path Forward: The "Start and Sort" Approach
Given the high clinical suspicion, the chronicity of the illness (since 2024), and the negative initial workup, here is a synthesized, pragmatic plan.
#### Phase 1: Initiate Empirical Treatment & Immediate Logistics
- *Action:* Start Antitubercular Therapy (ATT) *tomorrow*, as suggested by Dr. PPM1.
- *Rationale:*
- *Preventing Progression:* The patient has been symptomatic for nearly two years. Delaying treatment further risks progression of lung damage and continued morbidity.
- *Diagnostic Clarity via Response:* In high-burden settings, a positive response to ATT within 2-4 weeks (reduction in fever, improved appetite, weight gain) serves as a powerful piece of "therapeutic evidence" supporting the diagnosis.
- *Cost-Effectiveness:* Waiting for costly tests that the family struggles to afford can be counterproductive if the clinical picture is clear.
#### Phase 2: Concurrent Investigation (Do Not Delay Treatment for Tests)
Since the family is arranging funds, use this window to gather more data without delaying the start of medication.
- *HRCT Chest (as planned):* This is an excellent next step.
- *Utility:* It will better characterize the "suspicious shadows" seen on X-ray. It can show a miliary pattern, tree-in-bud nodules (endobronchial spread), cavitation, or lymphadenopathy, which can strengthen the TB diagnosis and rule out other differentials (like malignancy or interstitial lung disease).
- *Baseline:* It provides a baseline for monitoring treatment response later.
- *Bronchoscopy with BAL (as planned):*
- *Utility:* This is the gold standard for diagnosing sputum-negative TB.
- *Specimens:* Send the BAL fluid for:
1. *CBNAAT / GeneXpert:* To confirm the diagnosis and check for Rifampicin resistance.
2. *AFB Smear and Culture: * Culture is the gold standard, though it takes weeks. It is crucial for drug susceptibility testing (DST) if the patient doesn't improve or if there's a suspicion of drug resistance later.
3. *Fungal Studies:* To rule out fungal infections like aspergilloma or histoplasmosis, which can mimic TB.
4. *Cytology:* To rule out malignancy, which is a crucial differential in a 56-year-old with weight loss.
### Summary of Recommendations for the Team
1. *Medication:* Start standard weight-based ATT (Isoniazid, Rifampicin, Pyrazinamide, Ethambutaxel) *tomorrow*.
2. *Investigations:* Proceed with HRCT and Bronchoscopy as funds permit. Frame these to the family not as "tests to decide if we treat," but as "tests to confirm the diagnosis and ensure we are using the right medicines, now that we are starting them."
3. *Monitoring:* Document the clinical response meticulously. The resolution of fever and night sweats in the coming weeks will be your best confirmation of the diagnosis.
4. *Differential:* Keep a broad mind. If the patient does not improve on ATT after 4-6 weeks, or if the HRCT shows atypical features, revisit the differential diagnosis (e.g., fungal infections, non-tuberculous mycobacteria [NTM], malignancy, Wegener's granulomatosis).
5. *Documentation:* Dr. PPM3, please ensure the Chest/TB consult note is uploaded to the e-log for completeness.
This approach balances the need for evidence-based medicine with the practical realities of clinical care in resource-constrained settings, prioritizing the patient's immediate well-being.(DeepSeek)
No comments:
Post a Comment